His research interest lies in discovering and understanding novel receptor-ligand pathways with immune-modulatory functions and how to best utilize them as potential targets for cancer immunotherapy. During these years, Dr. Wang developed several genome-scale proprietary screening platforms leading to valuable industrial partnerships, some of which formed the basis of NextCure, Inc. He has discovered several first-in-class targets, such as FGL1/LAG-3 and Siglec-15, which represent novel tumor immune evasion mechanisms and new approaches for cancer immunotherapy. The first-in-human cancer clinical trials targeting the Siglec-15 pathway are currently ongoing at Yale and NYU, in addition to other sites. Moreover, Dr. Wang also examined the mechanisms of anti-tumor efficacy versus liver toxicity of agonistic anti-CD137 (4-1BB) therapy and provided new insights for alleviating liver pathology without disruption of anti-tumor immunity.Moving forward, Dr. Wang is planning to use innovative technologies to identify key mechanisms within the tumor microenvironment in the control of anti-tumor immunity and to design useful next-generation cancer immunotherapies with rational biomarkers.